D-dimers

DD-XLink-mab

Monoclonal antibody against crosslinked fibrin ("D-dimer")
Quantity Unit Price Status
100 µg 400 € Available
Documents
Art. No.
A076
Background info
After proteolytic activation by thrombin, FXIIIa modifies the soft fibrin clot and thereby introducing covalent bonds. First, cross-linking between abutting γ-chains of fibrin is catalyzed and subsequently α2-antiplasmin is incorporated to further increase the resistance against fibrinolysis. Plasmin catalyses the retarded clot dissolution and the release of crosslinked fibrin degradation products (xFDPs / D-dimer). Monoclonal “D-dimer” antibodies (e.g. DD-3B6/22) are commercially available and are used in In Vitro Diagnostics (IVD) to exclude thromboembolic events. However, these monoclonals do not detect the crosslink itself but address a portion of polypeptides within the D-domain after plasmin degradation that are conformationally reactive. Zedira scientists developed a monoclonal antibody which directly recognizes the crosslinked fibrin neoepitope (DD-XLink-mab).

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Host
Mouse
Isotype
IgG2b κ
Immunogen
Human fibrin peptides cross-linked with plasma factor XIIIa
Specificity
Specific for clot derived xFDPs (crosslinked Fibrin Degradation Products) Minor reactivity with fibrinogen degradation products (FDPs) cannot be excluded (compare to ELISA data, see figure 3 in PDS).
Formulation
The antibody is stored in PBS, 150 mM NaCl (pH 7.4), 0.02% sodium azide
Working dilutions
Optimal dilutions should be determined by the end user. E. g. for Western-Blotting: 1 / 3,000 to 1 / 10,000 should be suitable
Storage
Store at 2 – 8 °C
Note
NOTE INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.
Related Products

News

Blog

Events